Skip to content

Study on the effect and adverse effects of intrathecal morphine for analgesia after cesarean delivery

Study on the effect and adverse effects of intrathecal morphine for analgesia after cesarean delivery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500100912
Enrollment
Unknown
Registered
2025-04-17
Start date
2025-05-01
Completion date
Unknown
Last updated
2025-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative analgesia

Interventions

150ug morphine: intrathecal injection of 150ug morphine
200ug morphine: intrathecal injection of 200ug morphine
250ug morphine:intrathecal injection of 250ug morphine

Sponsors

The General Hospital of the PLA Northern Command
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing elective cesarean section in the General Hospital of the Northern Theater of Operations; 2. voluntarily participate and sign the informed consent form; 3. >= 37 weeks of gestation, age 20~35 years old, ASA grade II., height 150~170cm, body mass index BMI<35kg/m^2; 4. No contraindication to neuraxial anesthesia, subarachnoid block anesthesia and successful block (plane T6 or above).

Exclusion criteria

Exclusion criteria: 1. Have a mental illness that prevents normal communication, refuses to participate in the trial, or is unable to give informed consent; 2. Severe cardio-cerebral and pulmonary diseases, including unstable angina, myocardial infarction, ventricular dysfunction, and increased intracranial pressure; 3. severe pregnancy-induced hypertension; 4. gastrointestinal diseases, including gastrointestinal obstruction; 5. hepatic insufficiency; 6. History of motion sickness and obvious nausea and vomiting during pregnancy; 7. Recent use of opioid analgesics and sedative drugs or preoperative use of antipruritus drugs; 8. Allergies to related drugs; 9. Subarachnoid block anesthesia failure or poor anesthetic effect.

Design outcomes

Primary

MeasureTime frame
effective analgesia time;

Secondary

MeasureTime frame
severity and duration of itching;severity of nausea and vomiting;

Countries

China

Contacts

Public ContactCao Huijuan

The General Hospital of the PLA Northern Command

caohuijuan12@sina.com+86 133 0988 0882

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026